Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Baker Hughes Co (BKR) vs Crispr Therapeutics AG (CRSP) Price & Performance

Baker Hughes CoTrade
Crispr Therapeutics AGTrade

Price performance (Past 24H)

Key statistics

Baker Hughes Co vs Crispr Therapeutics AG — how do they compare? Baker Hughes Co trades at $64.74 (market cap $64.34B), while Crispr Therapeutics AG trades at $54.08 (market cap $5.23B). The key difference: Baker Hughes Co is far larger — about 12.3× Crispr Therapeutics AG's market cap, and Baker Hughes Co pays a 1.42% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.

BKRCRSP
Market Cap
$64.34B$5.23B
Sector
EnergyHealth
52-Week High
$69.67$76.78
52-Week Low
$42.51$44.34
Enterprise Value
$64.86B$3.65B
Dividend Yield
1.42%

Returns comparison

Trailing returns across standard periods

About Baker Hughes Co

Baker Hughes is a global leader in oilfield services and oilfield equipment, with particularly strong presences in the artificial lift, specialty chemicals, and completions markets. The other half of its business focuses on industrial power generation, process solutions, and industrial asset management, with high exposure to the liquid natural gas market specifically, as well as broader industrials end markets.

Read more on BKR

About Crispr Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Read more on CRSP